阿尔特苏纳酸通过cGMP-PKG信号传递改善了对类风湿性关节炎的骨损伤的低反应
Fengyu Huang1, Peiping Chen2, Xinzhuo Zhang2
1Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
概括
阿尔特苏纳酸 (ARS) 通过改善非响应者的反应来增强类风湿性关节炎 (RA) 中的莱夫卢诺米德 (LEF) 疗效. ARS通过cGMP-PKG通路准骨质细胞活动,为RA治疗提供了一种新的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
背景情况:
- 莱弗卢诺胺 (LEF) 是一种用于治疗类风湿性关节炎 (RA) 的第一线疾病修饰性抗风湿药物 (DMARD).
- 在患有严重骨损伤和低于最佳反应的患者中,LEF的治疗疗效通常是有限的.
- 阿尔特苏纳酸 (ARS) 是一种阿尔特美西宁衍生物,显示出抑制骨质细胞分化和改善RA骨破坏的潜力.
研究的目的:
- 评估ARS是否可以增强LEF在缓解RA骨损伤中的有效性.
- 阐明ARS增强LEF疗效的潜在机制.
主要方法:
- 利用原诱导性关节炎 (CIA) 鼠标模型来识别LEF低响应者.
- 研究了ARS克服LEF抗性的能力,并减轻这些小鼠的骨破坏.
- 结合体内和体外评估,包括转录组分析,以确定机制.
主要成果:
- 54%的LEF治疗小鼠表现出不良反应;ARS显著改善了这些小鼠的关节炎症和骨损伤.
- 在实验室中,ARS和LEF协同抑制了骨质细胞形成和骨再吸收.
- 通过激活循环氨酸单酸 (cGMP) -cGMP依赖蛋白激酶 (PKG) 途径并降低TRAF6/NFATc1轴的调节,ARS增强了骨质细胞抑制.
结论:
- 通过激活cGMP-PKG通路并抑制TRAF6/NFATc1介导的骨质结晶生成,ARS提高了RA中的LEF反应能力.
- 这些发现为探索RA患者的组合疗法提供了基础,RA患者的LEF反应较差.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
454
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
454
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
437
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
437
01:21Rheumatic Heart Disease III: Medical Management
263
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
263
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
439
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
439